Regulatory effects of endogenous interleukin-1 receptor antagonist protein in immunoglobulin G immune complex-induced lung injury.
Open Access
- 15 February 1996
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 97 (4) , 963-970
- https://doi.org/10.1172/jci118520
Abstract
IL-1 receptor antagonist (IL-1Ra) has regulatory effects on IL-1 activity both in vitro and in vivo. In the IgG immune complex model of lung injury in rats, exogenously administered human IL-1Ra suppressed neutrophil recruitment and ensuing lung injury. In this study, we sought to determine if endogenous rat IL-1Ra might regulate this lung-inflammatory response. By Northern blot analysis of lung mRNA and Western analysis of bronchoalveolar lavage (BAL) fluids, rat IL-1Ra expression was found to increase during development of inflammation in IgG immune complex-mediated alveolitis. By immunostaining, alveolar macrophages and recruited neutrophils were the apparent sources of IL-1Ra. In vivo blocking of endogenous IL-1Ra resulted in a 53% increase in lung vascular permeability and a 180% increase in BAL fluid neutrophils. In companion studies, a significant increase in IL-1beta was found, whereas no significant change in TNF-alpha activity was observed. Whereas the in vivo regulatory effects of IL-1R appear to be limited to IL-1beta, IL-10 regulates both IL-1beta and TNF-alpha in this model, reflected by a 48% increase in BAL IL-1beta in rats treated with anti-IL-10. These findings suggest that IL-1Ra is an intrinsic regulator of inflammatory injury after deposition of IgG immune complexes and that it regulates production of IL-1beta.Keywords
This publication has 48 references indexed in Scilit:
- Protective effects of IL-4 and IL-10 against immune complex-induced lung injury.The Journal of Immunology, 1993
- Endogenous IL-1 receptor antagonist protein (IRAP) regulates schistosome egg granuloma formation and the regional lymphoid response.The Journal of Immunology, 1993
- Levels of synovial fluid interleukin‐1 receptor antagonist in rheumatoid arthritis and other arthropathies. potential contribution from synovial fluid neutrophilsArthritis & Rheumatism, 1993
- Regulation of Interleukin-1ra, Interleukin-1α, and Interleukin-1β Production by Human Alveolar Macrophages with Phorbol Myristate Acetate, Lipopolysaccharide, and Interleukin-4American Journal of Respiratory Cell and Molecular Biology, 1993
- IL-1 receptor antagonist release is regulated differently in human alveolar macrophages than in monocytesJournal of Applied Physiology, 1992
- Immune complex-induced lung and dermal vascular injury. Differing requirements for tumor necrosis factor-alpha and IL-1.The Journal of Immunology, 1992
- Recombinant interleukin-1 receptor antagonist blocks the proinflammatory activity of endogenous interleukin-1 in rabbit immune colitisGastroenterology, 1992
- Expression and Regulation of Human Alveolar Macrophage-derived Interleukin-1 Receptor AntagonistAmerican Journal of Respiratory Cell and Molecular Biology, 1992
- Interleukin-1 receptor antagonist circulates in experimental inflammation and in human disease.1992
- Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia.Journal of Clinical Investigation, 1992